The Tri-I TDI, a partnership established in 2013 to expedite early-stage drug discovery of innovative new small molecule therapies, announced today that it will expand its scope to support the development of antibody drug discovery. More »
The Tri-I TDI, a partnership established in 2013 to expedite early-stage drug discovery of innovative new small molecule therapies, announced today that it will expand its scope to support the development of antibody drug discovery. More »
